Articles By Jack Cush, MD
Celecoxib Shines and Naproxen Tanks in the PRECISION Study
The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)
Read Article
ACR 2016 – Day 2 Highlights
Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.
Read Article
ACR 2016 – Day 1 Highlights
The annual ACR meeting began last night with a number of famed rheumatologists being inducted as ACR Masters.
Read Article
CORRONA Presentations at ACR 2016
CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.
Read Article
Two New Biologics for Polyarticular JIA
On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.
Read Article
RheumNow Week in Review – 11 November 2016
Dr Cush reviews highlights from this week on RheumNow.com
Read Article
The ACR 2016 Playbook
For me and many others, this is the Super Bowl of meetings. I haven’t missed an ACR meeting since I started going as a fellow in 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 14,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, a gigantic Costco (on Saturday), and a sold-out concert.
Read Article
The Long Awaited PRECISION Study
The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.
Read Article
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
